salvigenin has been researched along with hispidulin in 2 studies
Studies (salvigenin) | Trials (salvigenin) | Recent Studies (post-2010) (salvigenin) | Studies (hispidulin) | Trials (hispidulin) | Recent Studies (post-2010) (hispidulin) |
---|---|---|---|---|---|
27 | 0 | 19 | 123 | 0 | 76 |
Protein | Taxonomy | salvigenin (IC50) | hispidulin (IC50) |
---|---|---|---|
nuclear receptor subfamily 0 group B member 1 | Homo sapiens (human) | 0.8337 | |
Serine/threonine-protein kinase pim-1 | Homo sapiens (human) | 2.71 | |
Dipeptidyl peptidase 4 | Sus scrofa (pig) | 0.49 | |
Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 0.3533 | |
MAP kinase-interacting serine/threonine-protein kinase 1 | Homo sapiens (human) | 1.205 | |
MAP kinase-interacting serine/threonine-protein kinase 2 | Homo sapiens (human) | 0.252 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Dong, ZX; Duan, JA; Gu, T; Li, NG; Shi, ZH; Tang, YP; Wang, ZJ; Wu, WY; Yang, JP; Zhang, PX; Zhang, W | 1 |
Chen, LC; Hsu, KC; Huang, HL; Huang, WJ; Lien, ST; Lin, TE; Ngo, ST; Pan, SL; Sung, TY; Tseng, HJ; Wu, YW; Yen, SC | 1 |
2 other study(ies) available for salvigenin and hispidulin
Article | Year |
---|---|
Synthesis and biological evaluation of methylated scutellarein analogs based on metabolic mechanism of scutellarin in vivo.
Topics: Animals; Antioxidants; Apigenin; Blood Coagulation Tests; Cell Survival; Dose-Response Relationship, Drug; Fibrinogen; Fibrinolytic Agents; Hydrogen Peroxide; Male; Methylation; Molecular Structure; PC12 Cells; Rabbits; Rats; Structure-Activity Relationship | 2015 |
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
Topics: Antineoplastic Agents; Apoptosis; Flavonoids; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Xenograft Model Antitumor Assays | 2021 |